[HTML][HTML] Sizing up pharmacotherapy for obesity
MA Valentino, A Terzic, SA Waldman - Clinical and translational …, 2010 - ncbi.nlm.nih.gov
Obesity has increased over the last 20 years, from a condition affecting only a small portion
of populations in developed countries, into a global pandemic. 1 The impact of obesity can …
of populations in developed countries, into a global pandemic. 1 The impact of obesity can …
[PDF][PDF] Pharmacotherapy for obesity-promise and uncertainty
SZ Yanovski - New England Journal of Medicine, 2005 - med.bpums.ac.ir
In 2005, a majority of adult Americans are overweight or obese, 1 putting millions of them at
increased risk for serious medical conditions, including cardiovascular disease, type 2 …
increased risk for serious medical conditions, including cardiovascular disease, type 2 …
The pharmaceutical market for obesity therapies
D Wong, K Sullivan, G Heap - Nature reviews. Drug discovery, 2012 - nature.com
Obesity has become one of the most significant public health challenges of the twenty-first
century. As a primary risk factor for type 2 diabetes, it is closely associated with the metabolic …
century. As a primary risk factor for type 2 diabetes, it is closely associated with the metabolic …
Current options for the pharmacotherapy of obesity
I Gouni-Berthold, HK Berthold - Current Pharmaceutical Design, 2019 - ingentaconnect.com
650 millions of adults are obese worldwide-in the US alone, forty percent of the adults are
obese. Although the obesity pandemic is constantly expanding at very high costs for health …
obese. Although the obesity pandemic is constantly expanding at very high costs for health …
Pharmacotherapy of obesity in complex diseases
VP Pulipati, S Pannain - Clinical obesity, 2022 - Wiley Online Library
More than 40% of adults in the United States suffer from obesity. Obesity is inextricably
linked to many chronic illnesses like type‐2 diabetes mellitus, hypertension, hyperlipidemia …
linked to many chronic illnesses like type‐2 diabetes mellitus, hypertension, hyperlipidemia …
Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy
Obesity is a chronic and complex disease associated with increased morbidity, mortality,
and financial burden. It is expected that by 2030 one of two people in the United States will …
and financial burden. It is expected that by 2030 one of two people in the United States will …
Can we win the war on obesity with pharmacotherapy?
JD Gotthardt, NT Bello - Expert review of clinical pharmacology, 2016 - Taylor & Francis
Introduction: Obesity is a major health concern for several countries. The United States (US)
has arguably led the world in the percentage of overweight and/or obese per capita for …
has arguably led the world in the percentage of overweight and/or obese per capita for …
Current updates in the medical management of obesity
Obesity is a chronic medical condition that is expected to become an indirect but leading
cause of mortality and morbidity. Obesity results in type 2 diabetes mellitus, insulin …
cause of mortality and morbidity. Obesity results in type 2 diabetes mellitus, insulin …
Pharmacotherapy for obesity: moving towards efficacy improvement
W Coutinho, B Halpern - Diabetology & Metabolic Syndrome, 2024 - Springer
Obesity is a chronic, recurring, progressive disease and a major public health problem
associated with several other diseases that lead to disability, morbidity, and mortality. The …
associated with several other diseases that lead to disability, morbidity, and mortality. The …
Emerging pharmacotherapy for obesity
LJ Aronne, AG Powell, CM Apovian - Expert opinion on emerging …, 2011 - Taylor & Francis
Introduction: Obesity is a rapidly increasing global health problem. The rates of obesity have
tripled over the past three decades and are predicted to rise even further. The need for safe …
tripled over the past three decades and are predicted to rise even further. The need for safe …